KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia. - Wikidata - wikimedia - TriplyDB

KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia.

KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia.

http://www.wikidata.org/entity/Q43158404

about

Genome-wide DNA methylation profiling of recurrent and non-recurrent chordomas.Targeting the PDGF signaling pathway in tumor treatment Somatic uniparental isodisomy explains multifocality of glomuvenous malformations.KANK1 inhibits cell growth by inducing apoptosis though regulating CXXC5 in human malignant peripheral nerve sheath tumors Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies.Multiple oligomerization domains of KANK1-PDGFRβ are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK.The platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) are major players in oncogenesis, drug resistance, and attractive oncologic targets in cancer.PDGFRB gain-of-function mutations in sporadic infantile myofibromatosis.PDGF-induced fibroblast growth requires monounsaturated fatty acid production by stearoyl-CoA desaturase.The tyrosine phosphatase SHP2 is required for cell transformation by the receptor tyrosine kinase mutants FIP1L1-PDGFRα and PDGFRα D842V.The Role of PDGFs and PDGFRs in Colorectal Cancer.PDGFRᵝ-Rearranged Myeloid Neoplasm with Marked Eosinophilia in a 37-Year-Old Man; And a Literature Review.ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor cell proliferation and differentiation into eosinophils: the role of nuclear factor-κB.Platelet-derived growth factors and their receptors in normal and malignant hematopoiesis PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies.PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib.Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.Involvement of platelet-derived growth factor ligands and receptors in tumorigenesis.Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms.Evaluation of Potential Mechanisms Controlling the Catalase Expression in Breast Cancer Cells.

P2860

Q33275514-3497086E-5260-4372-B13F-ACCFF381E2C6 Q34393461-DCB6C3E4-91DD-43FC-884D-BCC2D36563A2 Q36595136-F4D72B5F-439F-494B-B664-90AC4029B1B1 Q37571122-A8237D61-8743-48E1-B399-981F7FC16852 Q37919976-5919B59B-E060-490D-9A20-42034548B75F Q38620874-B06D260A-1225-41AC-8F7E-0D03C98B463A Q38832520-94D51223-65B1-4AFA-9532-E146DFB586FD Q38882182-BBCC4C25-139D-4637-B46F-598A818100C8 Q38911952-0585DB9D-D456-43CD-8EC6-ECA6A1BF6367 Q39016533-F1423A43-A6C4-4C8D-B680-33829196F740 Q39120772-6A1B53FA-19BF-4F39-BA88-A0BA7D9C4A4A Q39139762-46BA14FB-A2AC-4BAA-A0BA-06B4251258C8 Q39407253-1A6ABED9-03E6-429C-81F4-3E94B3EBC02B Q42126072-997B61FD-E07A-4FA2-9015-C56DA8E92B02 Q42623661-FB20DFBE-0128-402F-A943-9621B0BCAA9D Q42819833-3077C935-DE8B-413D-8972-1DE25EB18D27 Q46476524-FB9C2C3E-6041-4DE3-8007-AB06437AB619 Q47756210-ADF58984-EEEB-46D3-BD54-F97D4752E303 Q53350377-9E8075F6-DFE0-483B-87CA-42CB06CA9B1E Q53702202-4F3AD942-0BD3-4E33-9368-F62175549D57

P2860

KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia.

http://www.wikidata.org/entity/Q43158404

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

KANK1, a candidate tumor suppr ...... m with severe thrombocythemia.

@en

KANK1, a candidate tumor suppr ...... m with severe thrombocythemia.

@nl

type

label

KANK1, a candidate tumor suppr ...... m with severe thrombocythemia.

@en

KANK1, a candidate tumor suppr ...... m with severe thrombocythemia.

@nl

prefLabel

KANK1, a candidate tumor suppr ...... m with severe thrombocythemia.

@en

KANK1, a candidate tumor suppr ...... m with severe thrombocythemia.

@nl

P1433

Q43158404-CB3348A0-22D0-4DC9-BA51-AE14720B5B74

P1476

Q43158404-3AD6D202-E2F7-449B-8DFD-55A15BF77584

P2093

Q43158404-188E7D73-AF64-4419-BCB2-B82F99D5942D

Q43158404-5DD048AB-7045-4B76-84EB-8326819C5A2B

Q43158404-6B88FDF9-03C3-43FB-8FA8-77CAA4E6DA46

Q43158404-731D7B89-1CC2-4475-AE8E-1DC00365DA00

Q43158404-98FA071D-5E5A-411B-A9F4-9C8BA192FBBF

Q43158404-F2DAEF70-C5DB-4D2E-9267-718A587B18C2

Q43158404-F519A53B-E6DF-403E-9003-14CF0F7A229B

P2860

Q43158404-11690C66-E654-4CC0-8894-5BAC2B3D8096

Q43158404-28A46B80-78A5-413B-A8BE-611BD2E69D49

Q43158404-5C8D45D3-DE6E-4DD3-B246-754599938D07

Q43158404-8709658F-4610-405A-A2CA-194863D161FD

Q43158404-8E581560-F538-4545-8296-FA6610912381

Q43158404-B8EA3EA0-B8E7-474A-823E-09BE60AE8F74

Q43158404-F00F6DF7-582A-4BF6-8029-A311641ACA31

Q43158404-F7BB02E0-1E93-42B3-BA18-689D2D0F6A6C

P2888

Q43158404-B1F56176-029B-44C0-9802-13C61D06F4C9

P304

Q43158404-5313B9AE-7051-4B2A-8CAA-14B1899FF9F7

P31

Q43158404-BAAC11DB-D1AB-4112-9452-87AFE826F4D7

P356

Q43158404-2BAB860E-24C5-4A7B-AC45-93C80F4A9929

P433

Q43158404-9550F722-4801-4BBB-BF57-324C246010C3

P478

Q43158404-502DA3B7-8EC2-4F97-A80B-802E1A62BE09

P50

Q43158404-47EB59B7-7462-44CF-A20E-30A8FE57AA61

P577

Q43158404-F247154A-54A2-4333-8499-700D4ACB2090

P5875

Q43158404-9DBA91B4-A0E4-4887-9D86-7F5A814C53D4

P6179

Q43158404-08A02ED5-AD0E-48DB-8437-D05AD6EEE722

P698

Q43158404-7735110E-74A1-4ADA-8F2E-EC8E6974A12B

P356

P1433

P1476

KANK1, a candidate tumor suppr ...... m with severe thrombocythemia.

@en

P2093

A Ferrant

http://www.w3.org/2001/XMLSchema#string

F P Duhoux

http://www.w3.org/2001/XMLSchema#string

F Toffalini

http://www.w3.org/2001/XMLSchema#string

G Ameye

http://www.w3.org/2001/XMLSchema#string

H A Poirel

http://www.w3.org/2001/XMLSchema#string

J-M Libouton

http://www.w3.org/2001/XMLSchema#string

S Medves

http://www.w3.org/2001/XMLSchema#string

P2860

Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.

Oncogenic derivatives of platelet-derived growth factor receptors.

Contacts between membrane proximal regions of the PDGF receptor ectodomain are required for receptor activation but not for receptor dimerization.

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.

Kank proteins: structure, functions and diseases.

Deletion of the ANKRD15 gene at 9p24.3 causes parent-of-origin-dependent inheritance of familial cerebral palsy.

Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2.

A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease

P2888

P304

1052-1055

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2010.13

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Baptiste Demoulin

P577

2010-02-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41466393

http://www.w3.org/2001/XMLSchema#string

P6179

1005100763

http://www.w3.org/2001/XMLSchema#string

P698

20164854

http://www.w3.org/2001/XMLSchema#string